Potentially Disruptive Polymer-Based Bioresorbable Stent Data To Be Presented At EuroPCR 2011

Arterial Remodeling Technologies ("ART") announced today that details of the state-of-the-art design of its potentially disruptive polymer-based bioresorbable stent platform will be revealed, for the first time, at EuroPCR 2011 from the podium tomorrow (Wednesday, May 18). The disclosure will be presented by Antoine LaFont, M.D., Ph.D., Professor of Medicine, Head Interventional Cardiology Department, Georges Pompidou Hospital (Paris); and, Past Chairman, Interventional Cardiology Group, European Society of Cardiology (ESC). Dr. LaFont is a co-founder of ART.

Additionally, on Thursday, May 19, also at EuroPCR, Dr. LaFont will make a second presentation from the podium, disclosing additional data that further validates ART's innovative approach to simultaneously balance biocompatibility, biomechanics and bioresorption in a bioresorbable PLA (polylactic acid) stent. These data will show that ART's PLA-based stent can be overexpanded by up to 25% without any problems, thus avoiding the serious medical issues caused by cracking or malapposition.

"We will debunk the myth that polymer based stents are not optimal as a bioresorbable scaffold. Indeed, we have proven that overexpansion limitations are technology related and most definitely not related to the use of polymers in bioresorbable stents. Indeed, this represents a seminal truth, that precise vessel-sizing at implantation is not necessary with our bioresorbale stent due to its crack- and malapposition-free overexpansion features," said Machiel van der Leest, CEO, who previously was a co-founder and Chief Technology Officer of Minvasys. During his career he has developed and successfully introduced 15 Class III medical devices, which required pre-market approval and a scientific review to ensure safety and effectiveness.

"ART's stent is designed to have several critically important competitive advantages over currently marketed and in-development bioresorbable stents, including that our stent is designed to have (1) faster and smoother resorption, and (2) crack- and crazing-free expansion-which are very significant competitive advantage for our bioresorbable stent," explained van der Leest.

ART's novel biopolymers have been developed in conjunction with one of the world's leading authorities in polymer chemistry, Professor Michel Vert, who is Former Director of the Research Center for Artificial Biopolymers at France's National Center for Scientific Research (Centre National de Recherche Scientifique/CNRS).

Source:
Arterial Remodeling Technologies